• Je něco špatně v tomto záznamu ?

Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Renal Function

R. Sari Motlagh, A. Ghoreifi, T. Yanagisawa, T. Kawada, Z. Kikic, I. Gill, S. Daneshmand, H. Djaladat, SF. Shariat

. 2024 ; 10 (1) : 169-181. [pub] 20230711

Jazyk angličtina Země Nizozemsko

Typ dokumentu metaanalýza, časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007845

CONTEXT: There is no high-level evidence regarding the risk factors of glomerular filtration rate (GFR) loss following radical cystectomy (RC) and survival outcomes of patients with chronic kidney disease (CKD) undergoing RC. OBJECTIVE: To identify the risk factors of CKD in patients treated with RC for bladder cancer and to assess overall and oncological survival of patients with CKD who underwent RC. EVIDENCE ACQUISITION: According to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, two systematic reviews were performed for studies published before September 30, 2022, assessing (1) risk factors of renal function (RF) decline following RC and (2) overall and oncological outcomes of CKD patients treated with RC. EVIDENCE SYNTHESIS: A total of 21 and 17 studies were included for qualitative and quantitative syntheses, respectively. The first meta-analysis of ten studies (15 502 patients) identified these factors to be significantly associated with GFR loss following RC: advanced age, lower baseline RF, higher Charlson Comorbidity Index (CCI), diabetes mellitus, hypertension, postoperative hydronephrosis, ureteroenteric stricture, and locally advanced disease (hazard ratios [HRs] 1.03, 1.22, 1.5, 1.27, 1.24, 1.69, 1.92, and 5.13, respectively), while sex, preoperative hydronephrosis, perioperative chemotherapy, and diversion type were not. The second meta-analysis of seven studies (6900 patients) demonstrated significantly worse metastasis-free, cancer-specific, and overall survival in patients with higher CKD stages than in those with lower stages (HRs 1.54, 2.09, and 1.47, respectively). CONCLUSIONS: Current evidence suggests that older age, lower baseline RF, higher CCI, diabetes mellitus, hypertension, postoperative hydronephrosis, ureteroenteric stricture, and locally advanced disease are associated with long-term GFR loss following RC. In addition, patients with higher stages of CKD have worse long-term overall and oncological outcomes following RC. These data may help in counseling and decision-making regarding therapy and preventive measures. PATIENT SUMMARY: Several factors have been identified that can help identify patients at risk for glomerular filtration rate loss after radical cystectomy (RC). Chronic kidney disease is associated with poor cancer- and non-cancer-specific outcomes following RC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007845
003      
CZ-PrNML
005      
20240423160327.0
007      
ta
008      
240412s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2023.06.014 $2 doi
035    __
$a (PubMed)37442723
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Sari Motlagh, Reza $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
245    10
$a Survival of Patients with Chronic Kidney Disease Treated with Radical Cystectomy and Risk Factors of Glomerular Filtration Rate Loss Following Radical Cystectomy: Two Systematic Reviews and Meta-analyses of Interplay Between Radical Cystectomy and Renal Function / $c R. Sari Motlagh, A. Ghoreifi, T. Yanagisawa, T. Kawada, Z. Kikic, I. Gill, S. Daneshmand, H. Djaladat, SF. Shariat
520    9_
$a CONTEXT: There is no high-level evidence regarding the risk factors of glomerular filtration rate (GFR) loss following radical cystectomy (RC) and survival outcomes of patients with chronic kidney disease (CKD) undergoing RC. OBJECTIVE: To identify the risk factors of CKD in patients treated with RC for bladder cancer and to assess overall and oncological survival of patients with CKD who underwent RC. EVIDENCE ACQUISITION: According to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement, two systematic reviews were performed for studies published before September 30, 2022, assessing (1) risk factors of renal function (RF) decline following RC and (2) overall and oncological outcomes of CKD patients treated with RC. EVIDENCE SYNTHESIS: A total of 21 and 17 studies were included for qualitative and quantitative syntheses, respectively. The first meta-analysis of ten studies (15 502 patients) identified these factors to be significantly associated with GFR loss following RC: advanced age, lower baseline RF, higher Charlson Comorbidity Index (CCI), diabetes mellitus, hypertension, postoperative hydronephrosis, ureteroenteric stricture, and locally advanced disease (hazard ratios [HRs] 1.03, 1.22, 1.5, 1.27, 1.24, 1.69, 1.92, and 5.13, respectively), while sex, preoperative hydronephrosis, perioperative chemotherapy, and diversion type were not. The second meta-analysis of seven studies (6900 patients) demonstrated significantly worse metastasis-free, cancer-specific, and overall survival in patients with higher CKD stages than in those with lower stages (HRs 1.54, 2.09, and 1.47, respectively). CONCLUSIONS: Current evidence suggests that older age, lower baseline RF, higher CCI, diabetes mellitus, hypertension, postoperative hydronephrosis, ureteroenteric stricture, and locally advanced disease are associated with long-term GFR loss following RC. In addition, patients with higher stages of CKD have worse long-term overall and oncological outcomes following RC. These data may help in counseling and decision-making regarding therapy and preventive measures. PATIENT SUMMARY: Several factors have been identified that can help identify patients at risk for glomerular filtration rate loss after radical cystectomy (RC). Chronic kidney disease is associated with poor cancer- and non-cancer-specific outcomes following RC.
650    _2
$a lidé $7 D006801
650    _2
$a cystektomie $x škodlivé účinky $7 D015653
650    _2
$a hodnoty glomerulární filtrace $7 D005919
650    _2
$a stenóza $7 D003251
650    12
$a nádory močového měchýře $x chirurgie $7 D001749
650    12
$a chronická renální insuficience $x komplikace $x epidemiologie $7 D051436
650    _2
$a rizikové faktory $7 D012307
650    12
$a hydronefróza $x chirurgie $7 D006869
650    _2
$a ledviny $7 D007668
650    12
$a hypertenze $7 D006973
650    12
$a diabetes mellitus $x chirurgie $7 D003920
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Ghoreifi, Alireza $u Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
700    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Kikic, Zeljko $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Gill, Inderbir $u Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
700    1_
$a Daneshmand, Siamak $u Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
700    1_
$a Djaladat, Hooman $u Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: djaladat@med.usc.edu
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 10, č. 1 (2024), s. 169-181
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37442723 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160324 $b ABA008
999    __
$a ok $b bmc $g 2081698 $s 1217612
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 1 $d 169-181 $e 20230711 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace